Anticancer effects of crocetin in human esophageal squamous cell carcinoma KYSE-150 cells

Oncology Letters

Volumn 9, Issue 3, 2015, Pages 1254-1260

  Li, Sheng ^a   Jiang, Sheng ^a,b   Jiang, Wei ^a   Zhou, Yue ^a   Shen, Xiu Yin ^a   Luo, Tao ^a   Kong, Ling Ping ^a   Wang, Hua Qiao ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b SHANTOU CENTRAL HOSPITAL   (China)

Author keywords

Apoptosis; Cell cycle; Crocetin; Esophageal cancer; KYSE 150 cells

Indexed keywords

CASPASE 3; CROCETIN; PROTEIN BAX;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; MTT ASSAY; PROTEIN EXPRESSION; S PHASE CELL CYCLE CHECKPOINT; WESTERN BLOTTING;

EID: 84921743232     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2015.2869     Document Type: Article

References (47)

1. Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Cook MB, Chow WH and Devesa SS: Oesophageal cancer incidence in the United States by race, sex, and histologic type, 1977-2005. Br J Cancer 101: 855-859, 2009.
3. Szumiło J: Epidemiology and risk factors of the esophageal squamous cell carcinoma. Pol Merkur Lekarski 26: 82-85, 2009 (In Polish).
4. Rubenstein JH and Chen JW: Epidemiology of gastroesophageal reflux disease. Gastroenterol Clin North Am 43: 1-14, 2014.
5. Gaur P, Kim MP and Dunkin BJ: Esophageal cancer: Recent advances in screening, targeted therapy, and management. J Carcinog 13: 11, 2014.
6. Smith TJ, Ryan LM, Douglass HO Jr, et al: Combined chemoradiotherapy vs. radiotherapy alone for early stage squamous cell carcinoma of the esophagus: a study of the Eastern Cooperative Oncology Group. Int J Radiat Oncol Biol Phys 42: 269-276,1998.
7. Tepper J, Krasna MJ, Niedzwiecki D, et al: Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 26: 1086-1092, 2008.
8. Blazeby JM, Farndon JR, Donovan J and Alderson D: A prospective longitudinal study examining the quality of life of patients with eso-phageal carcinoma. Cancer 88: 1781-1787, 2000.
9. Blazeby JM, Williams MH, Brookes ST, et al: Quality of life measurement in patients with oesophageal cancer. Gut 37: 505-508,1995.
10. Kim T, Grobmyer SR, Smith R, et al: Esophageal cancer - the five year survivors. J Surg Oncol 103: 179-183, 2011.
11. Lin Y, Peng N, Li J, et al: Herbal compound triptolide synergistically enhanced antitumor activity of amino-terminal fragment of urokinase. Mol Cancer 12: 54, 2013.
12. Wang L, Lu A, Meng F, et al: Inhibitory effects of lupeal acetate of Cortex periplocae on N-nitrosomethylbenzylamine-induced rat esophageal tumorigenesis. Oncol Lett 4: 231-236, 2012.
13. Rasul A, Yu B, Khan M, et al: Magnolol, a natural compound, induces apoptosis of SGC-7901 human gastric adenocarcinoma cells via themitochondrial and PI3K/Akt signaling pathways. Int J Oncol 40: 1153-1161, 2012.
14. Bolhassani A, Khavari A and Bathaie SZ: Saffron and natural carotenoids: Biochemical activities and anti-tumor effects. Biochim Biophys Acta 1845: 20-30, 2014.
15. Ordoudi SA, Befani CD, Nenadis N, et al: Further examination of antiradical properties of Crocus sativus stigmas extract rich in crocins. J Agric Food Chem 57: 3080-3086, 2009.
16. Higashino S, Sasaki Y, Giddings JC, et al: Crocetin, a carotenoid from Gardenia jasminoides Ellis, protects against hypertension and cerebral thrombogenesis in stroke-prone spontaneously hypertensive rats. Phytother Res 28: 1315-1319, 2014.
17. Tsantarliotou MP, Poutahidis T, Markala D, et al: Crocetin administration ameliorates endotoxin-induced disseminated intravascular coagulation in rabbits. Blood Coagul Fibrinolysis 24: 305-310, 2013.
18. Nam KN, Park YM, Jung HJ, et al: Anti-inflammatory effects of crocin and crocetin in rat brain microglial cells. Eur J Pharmacol 648: 110-116, 2010.
19. Cai J, Yi FF, Bian ZY, et al: Crocetin protects against cardiac hypertrophy by blocking MEK-ERK1/2 signalling pathway. J Cell Mol Med 13: 909-925, 2009.
20. Yang R, Vernon K, Thomas A, et al: Crocetin reduces activation of hepatic apoptotic pathways and improves survival in experimental hemorrhagic shock. JPEN J Parenter Enteral Nutr 35: 107-113, 2011.
21. Khan MB, Hoda MN, Ishrat T, et al: Neuroprotective efficacy of Nardostachys jatamansi and crocetin in conjunction with selenium in cognitive impairment. Neurol Sci 33: 1011-1020, 2012.
22. Bathaie SZ, Hoshyar R, Miri H and Sadeghizadeh M: Anticancer effects of crocetin in both human adenocarcinoma gastric cancer cells and rat model of gastric cancer. Biochem Cell Biol 91: 397-403, 2013.
23. Li CY, Huang WF, Wang QL, et al: Crocetin induces cytotoxicity in colon cancer cells via p53-independent mechanisms. Asian Pac J Cancer Prev 13: 3757-3761, 2012.
24. Chryssanthi DG, Dedes PG, Karamanos NK, et al: Crocetin inhibits invasiveness of MDA-MB-231 breast cancer cells via downregulation of matrix metalloproteinases. Planta Med 77: 146-151, 2011.
25. Magesh V, DurgaBhavani K, Senthilnathan P, et al: In vivo protective effect of crocetin on benzo(a)pyrene-induced lung cancer in Swiss albino mice. Phytother Res 23: 533-539, 2009.
26. Song EL, Hou YP, Yu SP, et al: EFEMP1 expression promotes angiogenesis and accelerates the growth of cervical cancer in vivo. Gynecol Oncol 121: 174-180, 2011.
27. Gutheil WG, Reed G, Ray A, et al: Crocetin: an agent derived from saffron for prevention and therapy for cancer. Curr Pharm Biotechnol 13: 173-179, 2012.
28. Dhar A, Mehta S, Dhar G, et al: Crocetin inhibits pancreatic cancer cell proliferation and tumor progression in a xenograft mouse model. Mol Cancer Ther 8: 315-323, 2009.
29. Zhong YJ, Shi F, Zheng XL, et al: Crocetin induces cytotoxicity and enhances vincristine-induced cancer cell death via p53-dependent and -independent mechanisms. Acta Pharmacol Sin 32: 1529-1536, 2011.
30. Nurse P: A long twentieth century of the cell cycle and beyond. Cell 100: 71-78, 2000.
31. Nurse P, Masui Y and Hartwell L: Understanding the cell cycle. Nat Med 4: 1103-1106, 1998.
32. Dehay C and Kennedy H: Cell-cycle control and cortical development. Nat Rev Neurosci 8: 438-450, 2007.
33. Kastan MB and Bartek J: Cell-cycle checkpoints and cancer. Nature 432: 316-323, 2004.
34. Chu G: Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. J Biol Chem 269: 787-790, 1994.
35. Warner TF: Apoptosis. Lancet 2: 1252, 1972.
36. Wyllie AH: The biology of cell death in tumours. Anticancer Res 5: 131-136, 1985.
37. Amin A, Hamza AA, Bajbouj K, et al: Saffron: a potential candidate for a novel anticancer drug against hepatocellular carcinoma. Hepatology 54: 857-867, 2011.
38. Luo X, Budihardjo I, Zou H, et al: Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94: 481-490, 1998.
39. Li P, Nijhawan D and Wang X: Mitochondrial activation of apoptosis. Cell 116 (Suppl 2): S57-S59, 2004.
40. Porter AG and Jänicke RU: Emerging roles of caspase-3 in apoptosis. Cell Death Differ 6: 99-104, 1999.
41. Napier KJ, Scheerer M and Misra S: Esophageal cancer: A review of epidemiology, pathogenesis, staging workup and treatment modalities. World J Gastrointest Oncol 6: 112-120, 2014.
42. Javle M, Ailawadhi S, Yang GY, et al: Palliation of malignant dysphagia in esophageal cancer: a literature-based review. J Support Oncol 4: 365-373, 379, 2006.
43. Martin TA: The role of tight junctions in cancer metastasis. Semin Cell Dev Biol 36C: 224-231, 2014.
44. Liotta LA, Rao CN and Barsky SH: Tumor invasion and the extracellular matrix. Lab Invest 49: 636-649, 1983.
45. Mahadevan V and Hart IR: Metastasis and angiogenesis. Acta Oncol 29: 97-103, 1990.
46. Xiang M, Qian ZY, Zhou CH, et al: Crocetin inhibits leukocyte adherence to vascular endothelial cells induced by AGEs. J Ethnopharmacol 107: 25-31, 2006.
47. Umigai N, Tanaka J, Tsuruma K, et al: Crocetin, a carotenoid derivative, inhibits VEGF-induced angiogenesis via suppression of p38 phosphorylation. Curr Neurovasc Res 9: 102-109, 2012.